A Response to: Letter to the Editor Regarding ‘Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland’-Reference-Cited by-同舟云学术

A Response to: Letter to the Editor Regarding ‘Iron Formulations for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: A Cost-Effectiveness Analysis in Switzerland’

Published:2021-11-30 Issue:1 Volume:39 Page:815-821
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Aksan Aysegül,Schoepfer Alain,Juillerat Pascal,Vavricka Stephan,Bettencourt Miguel,Ramirez de Arellano Antonio,Gavata Simona,Morin Neige,Valentine William J.,Hunt Barnaby

Funder

Vifor Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-02001-4.pdf

Reference18 articles.

1. Aksan A, Schoepfer A, Juillerat P, et al. Iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a cost-effectiveness analysis in Switzerland. Adv Ther. 2021;38:660–77. https://doi.org/10.1007/s12325-020-01553-1.

2. Mun˜oz M, Reinisch W. Iron formulations for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: A cost-effectiveness analysis in Switzerland. Adv Ther. https://doi.org/10.1007/s12325-021-02000-5

3. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846-853.e1-2.

4. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008;103(5):1182–92.

5. Lautenschlager SA, Fournier N, Biedermann L, et al. The influence of breastfeeding, cesarean section, pet animals, and urbanization on the development of inflammatory bowel disease: data from the Swiss IBD cohort study. Inflamm Intest Dis. 2020;5(4):170–9.